| Ditemukan 1019 dokumen dengan kata kunci 5004 |
Simpan CSV  |
|
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
|
|
|
|
Bevacizumab plus chemotherapy continued beyond first progression in patients withmetastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings†
|
|
|
|
Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer
|
|
|
|
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
|
|
|
|
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensivedisease- small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
|
|
|
|
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial
|
|
|
|
Racial Disparity in Consultation, Treatment, and the Impact on Survival in Metastatic Colorectal Cancer
|
| No. Panggil: JNCI Journal of the National Cancer Institute; Volume 105, No.23, 4 December 2013: p.1814-1820 |
|
|
Koleksi: Artikel Internasional - Oxford ::
Cari yang mirip ::
Tambahkan ke Favorit ::
|
|
|
FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
|
|
|
|
Prospective Study of Family History and Colorectal Cancer Risk by Tumor LINE-1 Methylation Level
|
| No. Panggil: JNCI Journal of the National Cancer Institute; Volume 105, No.2, 16 January, 2013: p.130-140 |
|
|
Koleksi: Artikel Internasional - Oxford ::
Cari yang mirip ::
Tambahkan ke Favorit ::
|
|
|
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
|
|
|
Hasil Pencarian
